MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/annrheumdis-2015-209087

Медицинская библиотека · Annals of the rheumatic diseases · 2016

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

Humbert Marc, Coghlan J Gerry, Ghofrani Hossein-Ardeschir, Grimminger Friedrich, He Jian-Guo, Riemekasten Gabriela, Vizza Carmine Dario, Boeckenhoff Annette, Meier Christian, de Oliveira Pena Janethe, Denton Christopher P

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The 12-week, phase III Pulmonary Arterial hyperTENsion sGC-stimulator Trial (PATENT)-1 study investigated riociguat in patients with pulmonary arterial hypertension (PAH). Here, we present a prospectively planned analysis of the safety and efficacy of riociguat in the subgroup of patients with PAH associated with connective tissue disease (PAH-CTD).

METHODS

Patients with PAH-CTD were further classified post hoc as having PAH associated with systemic sclerosis or PAH-other defined CTD. In PATENT-1, patients received riociguat (maximum 2.5 or 1.5 mg three times daily) or placebo. Efficacy endpoints included change from baseline in 6-minute walking distance (6MWD; primary endpoint), haemodynamics and WHO functional class (WHO FC). In the long-term extension PATENT-2, patients received riociguat (maximum 2.5 mg three times daily); the primary endpoint was safety and tolerability.

RESULTS

In patients with PAH-CTD, riociguat increased mean 6MWD, WHO FC, pulmonary vascular resistance and cardiac index. Improvements in 6MWD and WHO FC persisted at 2 years. Two-year survival of patients with PAH-CTD was the same as for idiopathic PAH (93%). Riociguat had a similar safety profile in patients with PAH-CTD to that of the overall population.

CONCLUSIONS

Riociguat was well tolerated and associated with positive trends in 6MWD and other endpoints that were sustained at 2 years in patients with PAH-CTD.

TRIAL REGISTRATION NUMBERS: PATENT-1 (NCT00810693), PATENT-2 (NCT00863681).

Для цитирования: Humbert Marc, Coghlan J Gerry, Ghofrani Hossein-Ardeschir, Grimminger Friedrich, He Jian-Guo, Riemekasten Gabriela, Vizza Carmine Dario, Boeckenhoff Annette, Meier Christian, de Oliveira Pena Janethe, Denton Christopher P. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.. Annals of the rheumatic diseases. 2016. DOI: 10.1136/annrheumdis-2015-209087.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.